Last10K.com

Ascendis Pharma As (ASND) SEC Filing 6-K Foreign Issuer report for the period ending Monday, October 7, 2019

Ascendis Pharma As

HISTORY TOOLS
CIK: 1612042 Ticker: ASND

View differences made from one to another to evaluate Ascendis Pharma As's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Ascendis Pharma As.

Continue

Assess how Ascendis Pharma As's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Ascendis Pharma As's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Material Contracts, Statements, Certifications & more

Ascendis Pharma As provided additional information to their SEC Filing as exhibits

Exhibit 1.1: Underwriting Agreement
Ticker: ASND
CIK: 1612042
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001193125-19-263919
Submitted to the SEC: Mon Oct 07 2019 7:01:36 PM EST
Accepted by the SEC: Tue Oct 08 2019
Period: Monday, October 7, 2019
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/asnd/0001193125-19-263919.htm